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pen accessAbstract A speciﬁc, sensitive and rapid method based on high performance liquid chromatogra-
phy (HPLC) was developed for the simultaneous determination of telmisartan (TELM) and hydro-
chlorothiazide (HCT) in human plasma using indapamide as internal standard. The method utilizes
proteins precipitation with acetonitrile as only sample preparation prior to RP-HPLC.
The analytes were chromatographed on shim-pack cyanopropyl column in isocratic elution with
methanol: 10 mM ammonium acetate solution (pH 6.0) (35:65 v/v) as mobile phase at a ﬂow rate
of 1 ml/min and the wavelength of detection was 270 nm.
The method was validated over the concentration range of 1–10 lg ml1 for TELM and 0.31–
3.12 lg ml1 for HCT in human plasma.
Inter- and intra-run precision of TELM and HCT were less than 3.60% and the accuracy was less
than 1.868%. The linearity, recovery, matrix effect and stability were validated for TELM/HCT in
human plasma.
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Telmisartan (TELM), 40-[(1,40-dimethyl-20-propyl[2,60-bi-1H-
benzimidazol]-10-yl)methyl][1,10-biphenyl]-2-carboxylic acid1;
It is a newly developed drug, which is angiotensin II receptor
antagonist, used in the treatment of hypertension. Telmisartan
is not ofﬁcial in IP, BP, and USP. Hydrochlorothiazide is
chemically 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-
sulphonamide-1,1-dioxide. It is ofﬁcial in IP’96,2 BP 20043
and USP 2006.4 The two drugs are of limited metabolism
and eliminated unchanged from human body.5
Detailed survey of literature of telmisartan revealed several
methods for its determination in pharmaceutical formulations
like, electrochemical6,7 and HPLC8,9 also telmisartan was
determined in human plasma10–12 and in urine.13 Similarly, a
20 I. Salamasurvey of literature of hydrochlorothiazide revealed that it has
been measured in biological ﬂuid both by HPLC14–16 and
electrochemical17 methods. UV spectrophotometric, TLC,
and spectroﬂuorimetric methods were found to be reported
for the determination of telmisartan and hydrochlorothiazide
in a combined dosage form.18 Two HPLC methods for
determination of telmisartan and hydrochlorothiazide in
pharmaceutical preparation19,20 were also reported. Liquid
chromatographic–tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothi-
azide in human plasma21 was also reported; this method
required long time for preparation of samples, relied on te-
dious liquid–liquid extraction procedure, used complicated
gradient elution and expensive equipments.
Therefore, it was desirable to develop simple, accurate,
cheap and fast procedure that could be applied for the simul-
taneous determination of telmisartan and hydrochlorothiazide
in plasma after protein precipitation as the only sample prep-
aration step involved prior to reversed phase-HPLC.
The present work presents simple, rapid and sensitive eco-
nomical method for determination of TELM and HCT in hu-
man plasma compared to published methods. A good
separation of the analytes of this combination was achieved
by using a mobile phase containing ammonium acetate and
methanol as mobile phase. The proposed method is rapid, less
expensive, and is successfully applied for the simultaneous
determination of telmisartan and hydrochlorothiazide in hu-
man plasma; the method utilizes proteins precipitation with
acetonitrile as only sample preparation prior to RP-HPLC.2. Material and methods
2.1. Chemicals and reagents
Methanol and acetonitrile were of HPLC grade (Riedel-de
Haen laboratory chemicals, Germany). Ammonium acetate,
acetic acid, and NaOH used were of analytical grade.
The ammonium acetate buffer pH 6.0 was prepared by dis-
solving 0.77 g in liter of distilled water and pH was adjusted to
6.0 using acetic acid and 0.1 N NaOH.
Telmisartan and hydrochlorothiazide were kindly supplied
by alkan Pharma Cairo, Egypt) and certiﬁed to contain
99.7% and 99.8%, respectively, and used without further
puriﬁcation.
Biocardis tablets were manufactured under license of
Biopharma. Each tablet contains 80 mg TELM, 12.5 mg HCT.
Drug-free human plasma was obtained from hospital blood
bank.
2.2. Calibration standards (CS) and quality control (QC)
samples in human plasma
Stock solutions were prepared by dissolving each of TELM,
HCT and indapamide in methanol to obtain concentration
of 1 mg ml1 for each. The solution was prepared by dissolving
100 mg of each drug in sufﬁcient amount of methanol and the
volume was completed to 100 ml volumetric ﬂask with the
same solvent.
Working standard solutions were prepared by transferring
different volumes 0.5–5 ml of stock TELM and 0.155–
1.55 ml of stock HCT to 10 ml volumetric ﬂask and the volumeis completed with methanol. Volumes of 20 ll of working stan-
dard solutions and 20 ll of I.S. stock solution were added to
960 ll of drug-free human plasma to obtain drug concentra-
tion levels of 1–10 lg ml1 for TELM and 0.31–3.12 lg ml1
for HCT.
Quality control (QC) samples were prepared separately and
pooled at three different concentration levels (1, 5, and
10 lg ml1 for TELM and 0.62, 2.17, and 3.12 for HCT) as
low, medium and high, respectively. A calibration curve was
constructed from a blank sample (a plasma sample processed
without I.S.), a zero sample (a plasma processed with the
I.S.) and non-zero samples covering the total range 1–
10 lg ml1 for TELM and 0.31–3.12 lg ml1 for HCT.
2.3. Plasma sample preparation
The stored plasma samples were allowed to thaw at room tem-
perature before processing. The plasma samples were centri-
fuged at 4000 rpm for 10 min, an aliquot (0.96 ml) was
pipetted into a 10 ml polypropylene tube and acetonitrile
(2.0 ml) was added. The mixture was vortex mixed brieﬂy,
and after standing for 5 min at room temperature, the mixture
was centrifuged at 4000 rpm for 20 min. the supernatant was
carefully transferred into vial and injected into HPLC system.
2.4. Liquid chromatography/UV spectrophotometry
Plasma samples were analyzed using a HPLC (Shimadzu, Kyo-
to, Japan) instrument equipped with a model series LC-10
ADVP pump, SCL-10 AVP system controller, DGU-12A Deg-
asser, Rheodyne 7725i injector with a 20_l loop and a SPD-
10AVP UV–Vis detector. Separation and quantitation were
made on a Shim-pack cyanopropyl column (250 · 4.6 mm
(I.d.)) (5 l particle size). The detector was set at 270 nm. Data
acquisition was performed on class-VP software.
The mobile phase was composed of 10 mM ammonium ace-
tate solution (pH 6.0)–methanol (65:35, v/v). The ﬂow rate was
1 ml min1. The Injected volume was 20 ll. Detection was per-
formed with UV–Vis detector UV–Vis at k 270 nm.
2.5. Method validation
The method was validated for selectivity, matrix effect, preci-
sion, accuracy, linearity, sensitivity, recovery and stability
according to the US Food and Drug Administration
(FDA)22 guidelines for the validation of bioanalytical method.
The selectivity of this method was investigated by analyzing
six individual human blank plasma samples. Each blank sam-
ple was tested for interference using the present analytical
method and was compared with spiked sample whose concen-
tration of the analyte was at the LLOQ.
Calibration standard samples in human plasma were pre-
pared for three separate batches. Intra- and inter-batch preci-
sion and accuracy were evaluated by measurement of TELM
and HCT in plasma in ﬁve replicates of QC samples at three
different concentrations for three separate batches.
The matrix effect was investigated by comparing the calcu-
lated TELM/HCT concentration in spiked QC samples in six
biological matrices separately from different drug-free volun-
teers (A) and in mobile phase (B) at different concentration
levels. Similarly, the matrix effect on the I.S. was measured
from their peak areas at the working concentration level.
Simultaneous HPLC–UV analysis of telmisartan and hydrochlorothiazide in human plasma 21Matrix effect was deﬁned as the concentration or peak ratio
(A/B · 100). During the preparation of QCs or blank samples
at the same concentration level, each individual’s biological
matrix was used only once. The inter-subject variability of ma-
trix effect at every concentration level should be less than 15%
for acceptable performance.23
The stabilities of TELM and HCT in biological matrix and
working solutions at different storage conditions were evalu-
ated as follows and the results were expressed as percentage
recoveries (concentration of sample under different storage
condition/theory concentration).
The stabilities of TELM and HCT working solutions were
tested for 6 h at ambient temperature.
The stability of the studied drugs in human plasma was as-
sessed under different study conditions; i.e. standing at ambi-
ent temperature over 24 h (Bench top-stability) using QC
samples at low, medium and high concentration levels and
storing at 20 C for one month (long-term stability). QC
samples experiencing three freeze-thaw cycles (freeze–thaw sta-
bility) were analyzed together.
3. Results and discussion
To obtain the best chromatographic condition, different col-
umns and mobile phases with different pH and organic modi-
ﬁer were tested to provide sufﬁcient selectivity and sensitivity
in short separation time.
The best chromatographic condition take placed on cyano-
propyl column with mobile phase consisting of 10 mM ammo-
nium acetate solution (pH 6):methanol (65:35) at ﬂow rate
1 ml min1 and UV detection at 270 nm (Fig. 1).
The inﬂuence of both organic modiﬁer concentration and
pH were carefully studied Increasing organic modiﬁer concen-
tration not only improve peak shape and decrease the run time
but also decrease the method speciﬁcity due to the interference
of the HCT peak with endogenous biological substance.
Decreasing of organic modiﬁer concentration than 20%Figure 1 HPLC chromatogram of 20 lL injection of telmisartan
(Tel), hydrochlorothiazide (Hyd), and indapamide (Ind) as I.S.
spiked in human plasma.resulted in high speciﬁcity with regard to the separation of
the studied drug from endogenous biological substances, and
more retained of the drug on the column that led to excessive
tailing of eluting peaks and long run time.
Variation of pH plays an important role in the separation
process, at pH (3.5), TELM become more retained on the col-
umn. pH (6.0) was chosen as the optimum value both for res-
olution of drugs from endogenous biological substances and
better peak shape and reasonable run time.
One of the main reasons for using an internal standard is
for sample requiring signiﬁcant pretreatment or preparation
(ﬁltration, extraction) result in sample losses.
Properly chosen internal standard can be used to correct
sample losses. Indapamide was considered as best (I.S.)
applied for determination of TELM and HCT owing to reten-
tion characters that not affected seriously by change of pH, so
it eluted with reasonable resolution from TELM and HCT,
and absorbance characters that show high absorbance at the
chosen wave length (270 nm) that increase the sensitivity of
the method.
The proposed method succeeds in the determination of the
studied mixture in spiked plasma sample and also in real
patient plasma sample, 2 h following oral administration of
Biocardis tablets (80 mg TELM, 12.5 mg HCT) (Figs. 1 and 2).
4. Methods validation
4.1. Linearity
Linearity was established by analyzing six concentrations of
TELM and eight concentrations of HCT ranging between
1–10 and 0.31–3.12 lg ml1, respectively, by plotting the peak
area ratio against the corresponding concentration. Linearity
of the calibration graphs was validated by the high value of
the correlation coefﬁcient (>0.99) and the intercept value;
(Table 1). The calibration range for the proposed method
was established through considerations of the practical rangeFigure 2 HPLC chromatogram of 20 lL injection of patient
plasma sample, 2 h following oral administration of Biocardis
tablet (80 mg telmisartan and 12.5 mg hydrochlorothiazide).
Table 1 Assay parameters and regression characteristic of the
binary mixture determined by the proposed method.
Parameters Telmisartan Hydrochlorothiazide
Linearity range (lg ml1) 1–10 0.31–3.12
Detection limit (lg ml1) 0.054 0.043
Quantitation limit (lg ml1) 0.180 0.140
n 6 6
Slope (b) 0.046 0.529
S.D. of slope 0.001 0.009
R.S.D. of slope 2.170 1.720
Intercept (a) 0.006 0.022
S.D. of intercept 0.005 0.037
Correlation coeﬃcient (r) 0.997 0.999
S.E. of regression 0.004 0.084
Regression equation: A= a+ bc, where A is the absorbance, a is
the intercept, b is the slope and c is the concentration.
22 I. Salamarequired and the concentrations of TELM and HCT present in
the pharmaceutical product to give accurate, precise and linear
results (Table 1).
4.2. Accuracy
The method was repeated for different concentrations of pure
samples (quality control samples) at the low, medium and highTable 2 Validation results of the proposed method.
Analyte Added conc. (lg/ml) Found conc. (lg/ml) (mean ± S.D
TEL 1 0.890 ± 0.015
5 4.990 ± 0.067
10 10.100 ± 0.079
0.62 0.610 ± 0.005
HCT 2.17 2.070 ± 0.073
3.12 3.100 ± 0.073
aThe intraday (n= 3), average of three different concentrations repeated
bThe interday (n= 3), average of three different concentrations repeated
Table 3 Summary of stability of TELM & HCT in human plasma
Theoretical concentration (lg ml1)
Telmisartan
1 5 10
(a) Three freeze thaw cycles
Mean 0.983 5.02 10
S.D 0.015 0.10 0
RSD (%) 1.53 1.99 0
RE (%) 1.7 0.4 0
(b) Room temperature for 24 h
Mean 0.886 4.96 10
S.D. 0.015 0.067 0
R.S.D. (%) 1.69 1.35 0
RE (%) 11.4 0.8 0
(c) Re-injection after 30 days at 20 C
Mean 0.93 5.11 10
S.D. 0.02 0.135 0
R.S.D. (%) 2.15 2.64 0
RE (%) 7 2.2 0concentration levels, each repeated six times. The concentra-
tions were calculated each from its corresponding regression
equation. The recovery percentages and the mean recoveries
and the relative error (RE) were then calculated and the results
were shown in Table 2.
4.3. Precision
To measure the degree of method repeatability, the quality
control samples were analyzed each six times within the same
day and in three successive days as shown in Table 2.
4.4. Stability
The stability tests of the analytes were designed to cover ex-
pected conditions concerning the handling of clinical samples.
The stabilities of the analytes in human plasma were investi-
gated under various storage and processing conditions. The re-
sults are summarized in Table 3. The results indicate that TLM
and HCT were stable for the entire period of the experiment.
4.5. Selectivity and sensitivity
No endogenous source of interference was observed at the
retention times of the analytes. Typical chromatogram.) Intra-day R.S.D. (%) Inter-day R.S.D. (%) R.E. (%)
1.690 2.212 11.400
1.350 3.510 0.800
0.789 1.779 0.100
0.840 0.270 4.030
3.589 2.973 6.266
2.297 1.407 1.868
three times.
three times.
at varying condition.
Hydrochlorothiazide
0.62 2.17 3.12
.07 0.595 2.036 3.18
.087 0.005 0.072 0.075
.86 0.84 3.54 2.36
.7 4.03 6.18 1.92
.01 0.58 2.15 2.98
.079 0.01 0.07 0.02
.789 1.72 3.26 0.67
.1 6.45 0.92 4.49
.06 0.59 2.01 3.04
.081 0.01 0.05 0.08
.805 1.69 2.49 2.63
.6 4.84 7.37 2.56
Table 4 Statistical analysis of parameters required for system suitability testing of the proposed method.
Parameter Obtained value Reference value
TEL Ind HCT
Resolution (Rs) 4.650 5.000 R> 0.8
Relative retention (a) 2.250 2.660 >1
Tailing factor (T) 1.000 1.000 1.088 T= 1 for a typical symmetric peak
Capacity factor (K0) 9.000 4.000 1.500 1–10 Acceptable
Number of theoretical plates (N) 2220 3468.750 3468.750 Increases with eﬃciency of the separation
HETP (cm/plate) 0.011 0.007 0.007 The smaller the value, the higher the column eﬃciency
Simultaneous HPLC–UV analysis of telmisartan and hydrochlorothiazide in human plasma 23obtained from a plasma sample spiked with telmisartan,
hydrochlorothiazide, and indapamide is presented in (Fig. 1).
4.6. Determination of limit of quantitation and detection
For determining the limit of detection (LOD) and quantitation
(LOQ), the method based on the residual standard deviation of
a regression line and slope was adopted.24 To determine the
LOD and LOQ, a speciﬁc calibration curve was constructed
using samples containing the analytes in the range of LOD
and LOQ.
The LOD and LOQ for telmisartan and hydrochlorothia-
zide were estimated at a signal-to-noise ratio of 3:1 and 10:1,
respectively. The LODs for Telmisartan and hydrochlorothia-
zide were 0.018 and 0.022 lg ml1, and the LOQs were 0.052
and 0.068 lg ml1, respectively.
LOD and LOQ were calculated by using following
equations.
LOD ¼ Cd  Syx=b
LOQ ¼ Cq  Syx=b
where Cd/Cq is coefﬁcient for LOD/LOQ; Syx is residual var-
iance due to regression; b is slope.
4.7. Robustness
The proposed HPLC method proved robustness when i tried
to induce minor deliberate changes in the organic strength
(±1.5%) and the pH (±0.1 unit) of the mobile phase where
the retention time of the peaks was not signiﬁcantly affected
(±0.01 min).
4.8. Ruggedness
The proposed HPLC method showed ruggedness when we
tried to transfer our model to another lab with another HPLC
instrument (Shimadzu, Japan) in another city and running the
analysis via another fellow analyst as well, where the same re-
sults and retention times were obtained (±0.01 min) proving
no signiﬁcant lab to lab, instrument to instrument, analyst to
analyst and time to time variations and hence ruggedness of
the method.
4.9. System suitability studies
The resolution, number of theoretical plates, and peak asym-
metry were calculated for the working standard solutions
and are as shown in Table 4. The values obtained demon-strated the suitability of the system for the analysis of these
drugs in combination in human plasma.
4.10. Comparison of the proposed method with the reported
method
When comparing between the proposed method and the pub-
lished method for simultaneous determination of the binary
mixture21 found that:
 The suggested method is highly sensitive (linearity range;
1–10 lg ml1 for TELM and 0.31–3.12 lg ml1 for HCT)
when compared to the published method (linearity range;
1.00–600 ng ml1 for both analytes).
 The proposed method utilizes proteins precipitation with
acetonitrile as the only sample preparation involved prior
to reverse phase-HPLC rather than the other method that
depend on liquid–liquid extraction that need long time
and effort for sample preparation before injection, and also
the possibility of drug lost during preparation is high.
 The proposed method uses isocratic elution which is simple
compared to the other method which uses gradient elution,
also HPLC/UV is less expensive than LC–MS/MS.
 The published method however has shorter run time and
performed pharmacokinetic study.
5. Conclusion
The proposed HPLC method is a suitable technique for simul-
taneous determination of the binary mixture in human plasma.
The method is simple, accurate, and utilizes proteins precipita-
tion with acetonitrile as the only sample preparation prior to
RP-HPLC. The rapid, single step, plasma preparation coupled
with the simple HPLC–UV isocratic chromatographic appara-
tus makes the method cost-effective and suitable for analysis of
a large number of samples. The method was fully validated to
meet the requirements for sensitivity, accuracy and precision
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